Ann: Kazia presents to Bell Potter Healthcare Conference, page-4

I do not know but why did the presentation not mention what was announced on the first of August and clarify it further as the original announcement below is not clear imho , really need to be totally upfront with investors I feel and lay the cards on the table :

"Kazia has been advised by the Global Coalition for Adaptive Research (GCAR), the sponsor of the study, that the first stage of the paxalisib arm has completed recruitment. The treatment arm did not meet pre-defined criteria for continuing to a second stage, and patients enrolled in the first stage of the paxalisib arm will therefore continue on treatment as per protocol, and in follow-up, until completion of the final analysis, which Kazia anticipates receiving in 2H CY2023, as previously disclosed."